Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 59 VictozaⓇ maintains a strong position in the global DPP-IV, GLP-1 and SGLT-2 segment Segment value Share of segment value growth Segment value market shares DKK billion VictozaⓇ Other GLP-1 SGLT-2 DPP-IV 180 100% 100% 14% 12% 160 80% 80% 140 CAGR¹ value: 120 33.9% 60% 60% 100 80 40% 40% 60 40 14% 20% 20% 20 0 0% 0% Aug 2011 Aug 2016 2014 vs 2015 2015 vs Aug Aug 2016 2011 2016 1 CAGR for 5-year period Note: Segment only includes DPP-IV, GLP-1 & SGLT-2. Other oral anti-diabetic agents and insulin excluded Source: IMS MAT August 2016 value figures changing diabetes® novo nordisk

View entire presentation